Homology Medicines, Inc.


Homology Medicines, Inc. (Nasdaq: FIXX) is a genetic medicines company on a mission to advance its proprietary gene editing and gene therapy platform and transform the lives of patients by potentially curing rare genetic diseases. The company’s technology platform is based on a novel set of adeno-associated virus vectors derived from human hematopoietic stem cells (AAVHSCs) designed to precisely deliver genetic medicines in vivo either through gene therapy or the body’s natural DNA repair process of homologous recombination through nuclease-free gene editing.